Shire blasts Roche over its 'mis­lead­ing' case for trail­blaz­ing he­mo­phil­ia drug emi­cizum­ab, scor­ing in­junc­tion

Over the past year, Shire $SH­PG has seen its shares buf­fet­ed re­peat­ed­ly as Roche moved steadi­ly ahead with its late-stage pro­gram for its close­ly-watched he­mo­phil­ia A drug emi­cizum­ab (ACE910). Now it’s fight­ing back, tak­ing Roche to court over the week­end, ahead of any reg­u­la­to­ry de­ci­sion for a se­ries of what it claims are dam­ag­ing and mis­lead­ing com­ments about the drug’s rel­a­tive safe­ty and ef­fi­ca­cy. But Roche im­me­di­ate­ly fired back Mon­day morn­ing with more Phase III da­ta, with no sign that Shire’s as­sault had in­flu­enced its lat­est up­date.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.